Orchid Cellmark Posts 3.6 Percent Q1 Revenue Growth; Loss Rises on Legal Costs | GenomeWeb
NEW YORK (GenomeWeb News) – Orchid Cellmark said today that its first-quarter revenues rose 3.6 percent with US sales up 21 percent but offset by lower revenues in the UK. The firm’s net loss climbed 35.3 percent, which the firm said was primarily due to legal costs.
The Princeton, NJ-based DNA testing services firm brought in revenues of $14.5 million for the three-month period ended March 31, compared to revenues of $14 million in the first quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.